VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given
in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell
Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the
time it takes your lymphoma to get worse.